Go straight to the source.

Limitations: Emergency care requires clinical evaluation. This library does not provide an individualized sick-day or insulin plan.

Source checked 2026-09-30. See the original publication for full methods.

Limitations: Access year shown. Symptoms overlap with many conditions and cannot establish diabetes type.

Source checked 2026-09-30. See the original publication for full methods.

Limitations: Access year shown. Screening intervals and treatments depend on clinical findings.

Source checked 2026-09-30. See the original publication for full methods.

Limitations: Access year shown. Other kidney diseases can coexist; a single abnormal result is not a complete diagnosis.

Source checked 2026-09-30. See the original publication for full methods.

Limitations: Evidence through December 2025; few studies, limited prospective deployment, external validation and calibration.

Source checked 2026-09-30. See the original publication for full methods.

Limitations: Registry accessed in 2026. Enrollment and registration are not proof of efficacy; consult the live record for recruitment and results.

Source checked 2026-09-30. See the original publication for full methods.

Limitations: US guidance. Pregnancy criteria differ; screening must account for individual context.

Source checked 2026-09-30. See the original publication for full methods.

Limitations: Intervention evidence is strongest in selected high-risk trial populations.

Source checked 2026-09-30. See the original publication for full methods.

Limitations: Recommendations require shared clinical decisions; benefits and contraindications vary by drug.

Source checked 2026-09-30. See the original publication for full methods.

Limitations: Access, training, device labeling, and safe-use capacity affect applicability.

Source checked 2026-09-30. See the original publication for full methods.

Limitations: Treatment must consider nutrition, contraindications, access, and maintenance.

Source checked 2026-09-30. See the original publication for full methods.

Limitations: Evidence strength differs for diet, sleep, exercise, and psychosocial interventions.

Source checked 2026-09-30. See the original publication for full methods.

Limitations: Pediatric care requires developmental and family context; adult thresholds do not define a complete care plan.

Source checked 2026-09-30. See the original publication for full methods.

Limitations: Living patient resource; year denotes access year, not a newly published study.

Source checked 2026-09-30. See the original publication for full methods.

Limitations: Living reference accessed in 2026; red-cell disorders can make A1c unreliable.

Source checked 2026-09-30. See the original publication for full methods.

Limitations: Access year is shown; population risk factors do not establish an individual diagnosis.

Source checked 2026-09-30. See the original publication for full methods.

Population: Children aged 8–17 recently diagnosed with Stage 3 T1D

Sample: PROTECT: 328 participants

Limitations: June 12 accelerated approval based on C-peptide preservation, a surrogate. Confirmatory clinical benefit and label conditions matter.

Source checked 2026-09-30. See the original publication for full methods.

Limitations: US label. Age and staging criteria differ between indications; specialist evaluation and infection precautions are required.

Source checked 2026-09-30. See the original publication for full methods.

Limitations: Access year shown. Underlying trials often small, heterogeneous, or at risk of bias; products differ in composition.

Source checked 2026-09-30. See the original publication for full methods.

Limitations: Access year shown for a living textbook chapter; mechanistic biology is not a dosing guide.

Source checked 2026-09-30. See the original publication for full methods.

Limitations: Multiple pathways coexist; one explanatory model does not capture every T2D phenotype.

Source checked 2026-09-30. See the original publication for full methods.

Limitations: Historical educational account accessed in 2026; not a clinical evidence source.

Source checked 2026-09-30. See the original publication for full methods.

Population: Adults with BMI ≥27, T2D and HbA1c 7–10%

Sample: 1,206 randomized participants

Limitations: 68-week trial; weight and glycemia outcomes are not evidence of a permanent cure. Publication does not establish regulatory approval.

Source checked 2026-09-30. See the original publication for full methods.

Population: Selected adults with T1D, severe hypoglycemia and impaired awareness

Sample: 14 with ≥12-month follow-up; 12 at full dose

Limitations: Small, uncontrolled interim analysis; required immunosuppression; serious adverse events and deaths occurred. Not a routine cure.

Source checked 2026-09-30. See the original publication for full methods.

Population: One adult with long-standing T1D

Sample: 1 participant; 12-week reported follow-up

Limitations: Single participant, low cell dose and short follow-up. Does not demonstrate generalizable insulin independence.

Source checked 2026-09-30. See the original publication for full methods.

Population: Adults with obesity and prediabetes

Sample: 1,032 in the prediabetes analysis

Limitations: 176-week treatment and limited off-treatment follow-up; manufacturer-funded; prevention during therapy is not a permanent cure.

Source checked 2026-09-30. See the original publication for full methods.

Limitations: General patient education, not a substitute for emergency assessment.

Source checked 2026-09-30. See the original publication for full methods.

Population: UK adults with relatively recent T2D; selected extension participants

Sample: 85 extension participants assessed at 5 years

Limitations: Extension cohort selection and attrition; 13% is not the remission probability for all people with diabetes.

Source checked 2026-09-30. See the original publication for full methods.

Population: Global population; adult prevalence estimates

Limitations: Modeled estimates for 1990 and 2022; count, prevalence, incidence, and deaths are distinct measures.

Source checked 2026-09-30. See the original publication for full methods.

Population: Adults with T1D and repeated severe hypoglycemia despite intensive management

Sample: 30 in two nonrandomized single-arm studies

Limitations: Selected population, donor constraints and risks of infusion and immunosuppression. Approval does not establish universal cure.

Source checked 2026-09-30. See the original publication for full methods.

Limitations: Narrow retinal screening workflow; results do not validate general-purpose medical AI or all patient populations.

Source checked 2026-09-30. See the original publication for full methods.

Population: Women studied under experimentally restricted sleep

Limitations: Six-week physiological study; insulin sensitivity is a surrogate and the study does not establish long-term diabetes incidence.

Source checked 2026-09-30. See the original publication for full methods.

Population: Adults aged ≥20 across India

Sample: 113,043 participants surveyed during 2008–2020

Limitations: Cross-sectional estimates; survey timing varied by state and findings are not individual predictions.

Source checked 2026-09-30. See the original publication for full methods.

Population: Urban and rural India

Sample: 113,043 surveyed individuals

Limitations: Screening for undiagnosed diabetes is distinct from predicting incident disease; external calibration remains important.

Source checked 2026-09-30. See the original publication for full methods.

Limitations: Educational reference; transport pathways vary by tissue and experimental context.

Source checked 2026-09-30. See the original publication for full methods.

Population: High-risk relatives with presymptomatic T1D

Sample: 76 participants in TN-10

Limitations: Original evidence concerns delay of Stage 3, not prevention for everyone; see the current label for updated eligibility.

Source checked 2026-09-30. See the original publication for full methods.

Limitations: Different reviews disagree; biomarker improvement does not establish long-term complication benefit.

Source checked 2026-09-30. See the original publication for full methods.

Limitations: A consensus definition, not proof of permanent recovery or an instruction to stop medication.

Source checked 2026-09-30. See the original publication for full methods.

Limitations: Mechanistic synthesis, not an individual metabolic simulation.

Source checked 2026-09-30. See the original publication for full methods.

Limitations: Foundational mechanisms remain relevant; check current ADA guidance for clinical recommendations.

Source checked 2026-09-30. See the original publication for full methods.

Limitations: Foundational staging; rates vary by age and antibody profile. Use updated guidelines for monitoring.

Source checked 2026-09-30. See the original publication for full methods.

Limitations: Long-term observational follow-up of randomized T1D groups; not identical to every T2D population.

Source checked 2026-09-30. See the original publication for full methods.

Limitations: Historical mechanistic framework; not a complete causal account and not a prediction of individual outcomes.

Source checked 2026-09-30. See the original publication for full methods.

Population: US adults at high risk with elevated glucose and overweight

Sample: 3,234 randomized adults

Limitations: Relative risk reductions over about 3 years; not a guarantee for every individual or every prediabetes definition.

Source checked 2026-09-30. See the original publication for full methods.